Leadership Team
Our team combines drug discovery specialists with physicists, chemists and computer scientists committed to use cutting-edge technologies to make a difference to people’s lives.
Vid Stojevic, PhD
CEO, Co-founder
Expert in Quantum Physics and Artificial Intelligence
David Wright, PhD
CTO, Co-founder
Expert in Molecular Modelling and Simulation
Denise Moody
COO
Leader in Operations, ex-Roche, Bayer and AstraZeneca
Darren Millington
CFO
Seasoned Biotech Executive, ex-Summit and Rayner
Parminder Ruprah, PhD
Head of Chemistry, Co-founder
Highly experienced “Drug Hunter”, ex-Takeda and Pfizer
Cat Stace, PhD MBA
EVP of Business Development
Expert Computational Scientists
Our in-house expertise blends quantum physics, modelling, simulation, AI/ML and discovery/medicinal chemistry.
Jarryl D’Oyley, PhD
Project Manager, Co-founder
Georg Schusteritsch, PhD
Senior Quantum Scientist
Raphael Chantreau, PhD
Computational Drug Design
Charlie Adams, PhD
KTP Associate
Tim Katte, PhD
Computational Drug Design
Anthony Nash, PhD
Computational Drug Design
Alex Punter, PhD
Computational Drug Design
Will Gerrard, PhD
Computational Drug Design
Our Advisors
We are supported by an expert team of advisors that are working closely with us on corporate and business development, as well as, ongoing scientific development of our proprietary modelling and AI technology.
Key advisors include:
David Barrett, PhD
Seasoned Pharma Executive
Astellas Engineered Small Molecules UK
Prof. John Bridgewater
Clinical Professor
UCL
Prof. George Booth
Physics Professor
Kings College London
Prof. Adrian Mulholland
Head of Physical and Theoretical Chemistry
University of Bristol
Alessandra Cesano, PhD
Seasoned senior executive
ESSA Pharmaceuticals
Jarvist Moore-Frost, PhD
Royal Society Research Fellow
Imperial College London
Prof. Andrew Green
Chair of Condensed Matter Physics
UCL
Board of Directors
Antonio Benedetti
Executive Chairman
Darren Millington
Board Observer
Vid Stojevic
CEO
Mike Murphy
Board Observer
Sunil Shah
Non-Exec Director
Ted Witek
Board Observer
Andy Mulvaney
Non-Exec Director
Robert Hornby
Board Observer
David Wright
CTO
Our Partners
We are currently backed by a series of seed round investors, grants and academic partners.
AI Seed
AI and ML Fund
London, UK
Angel CoFund
Angel Investors
London, UK
o2h Ventures
Biotech & AI fund
Cambridge, UK
Wren Investments
Multi-family investments
London, UK
Meltwind
Biotech fund
Cambridge, UK
Syndicate Room
Angel network
Cambridge, UK
Cambridge Angels
Angel investors
Cambridge, UK